Acadia Pharmaceuticals Stock Performance
| ACAD Stock | USD 17.07 0.12 0.70% |
The firm owns a Beta (Systematic Risk) of 1.01, which signifies a somewhat significant risk relative to the market. ACADIA Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, ACADIA Pharmaceuticals is expected to follow. ACADIA Pharmaceuticals has an expected return of -0.72%. Please make sure to confirm ACADIA Pharmaceuticals total risk alpha, potential upside, and the relationship between the standard deviation and maximum drawdown , to decide if ACADIA Pharmaceuticals performance from the past will be repeated at some future date.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days ACADIA Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in May 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return (0.70) | Five Day Return (1.90) | Year To Date Return (44.69) | Ten Year Return (14.31) | All Time Return 154.78 |
1 | Disposition of 5577 shares by Stephen Davis of ACADIA Pharmaceuticals at 24.67 subject to Rule 16b-3 | 02/26/2024 |
2 | Acadia Pharmaceuticals to Participate in TD Cowens 44th Annual Health Care Conference on March 6, 2024 | 02/29/2024 |
3 | Oppenheimer cuts Acadia shares target to 19 from 25 | 03/12/2024 |
4 | Acquisition by Ndu Adora of 11045 shares of ACADIA Pharmaceuticals at 23.9 subject to Rule 16b-3 | 03/18/2024 |
5 | Nordea Investment Management AB Sells 12401 Shares of ACADIA Pharmaceuticals Inc. - Defense World | 03/21/2024 |
6 | Acquisition by Mark Schneyer of 24714 shares of ACADIA Pharmaceuticals subject to Rule 16b-3 | 03/25/2024 |
7 | Were Interested To See How ACADIA Pharmaceuticals Uses Its Cash Hoard To Grow | 03/27/2024 |
8 | ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 Shares | 03/28/2024 |
9 | Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference | 04/01/2024 |
10 | Insider Trading | 04/04/2024 |
11 | Disposition of 5275 shares by Mark Schneyer of ACADIA Pharmaceuticals subject to Rule 16b-3 | 04/05/2024 |
12 | Disposition of 2716 shares by Mark Schneyer of ACADIA Pharmaceuticals at 17.87 subject to Rule 16b-3 | 04/08/2024 |
13 | Acadia Pharmaceuticals EVP sells 48,534 in stock | 04/09/2024 |
14 | 3 Pharma Stocks to Sell in April Before They Crash Burn | 04/11/2024 |
15 | Acadia Pharmaceuticals Presents New DAYBUE Clinical Data at the 2024 American Academy of Neurology Annual Meeting | 04/17/2024 |
| Begin Period Cash Flow | 114.8 M |
ACADIA |
ACADIA Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 2,776 in ACADIA Pharmaceuticals on January 20, 2024 and sell it today you would lose (1,069) from holding ACADIA Pharmaceuticals or give up 38.51% of portfolio value over 90 days. ACADIA Pharmaceuticals is currently does not generate positive expected returns and assumes 3.0788% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than ACADIA, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ACADIA Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ACADIA Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ACADIA Pharmaceuticals, and traders can use it to determine the average amount a ACADIA Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2335
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ACAD |
Estimated Market Risk
| 3.08 actual daily | 27 73% of assets are more volatile |
Expected Return
| -0.72 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.23 actual daily | 0 Most of other assets perform better |
Based on monthly moving average ACADIA Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ACADIA Pharmaceuticals by adding ACADIA Pharmaceuticals to a well-diversified portfolio.
ACADIA Pharmaceuticals Fundamentals Growth
ACADIA Stock prices reflect investors' perceptions of the future prospects and financial health of ACADIA Pharmaceuticals, and ACADIA Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ACADIA Stock performance.
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.0686 | ||||
| Profit Margin | (0.08) % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 2.43 B | ||||
| Shares Outstanding | 164.77 M | ||||
| Price To Earning | (13.77) X | ||||
| Price To Book | 6.54 X | ||||
| Price To Sales | 3.89 X | ||||
| Revenue | 726.44 M | ||||
| Gross Profit | 145.49 M | ||||
| EBITDA | (67.83 M) | ||||
| Net Income | (61.29 M) | ||||
| Cash And Equivalents | 436.35 M | ||||
| Cash Per Share | 2.70 X | ||||
| Total Debt | 57.2 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 4.53 X | ||||
| Book Value Per Share | 2.62 X | ||||
| Cash Flow From Operations | 16.7 M | ||||
| Earnings Per Share | (0.37) X | ||||
| Market Capitalization | 2.81 B | ||||
| Total Asset | 748.96 M | ||||
| Retained Earnings | (2.43 B) | ||||
| Working Capital | 361.87 M | ||||
| Current Asset | 603.49 M | ||||
| Current Liabilities | 39.15 M | ||||
About ACADIA Pharmaceuticals Performance
To evaluate ACADIA Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when ACADIA Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare ACADIA Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand ACADIA Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents ACADIA's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 285.89 | 153.81 | |
| Return On Tangible Assets | (0.09) | (0.09) | |
| Return On Capital Employed | (0.15) | (0.16) | |
| Return On Assets | (0.08) | (0.09) | |
| Return On Equity | (0.14) | (0.15) |
Things to note about ACADIA Pharmaceuticals performance evaluation
Checking the ongoing alerts about ACADIA Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ACADIA Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ACADIA Pharmaceuticals generated a negative expected return over the last 90 days | |
| ACADIA Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 726.44 M. Net Loss for the year was (61.29 M) with profit before overhead, payroll, taxes, and interest of 145.49 M. | |
| ACADIA Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Acadia Pharmaceuticals Presents New DAYBUE Clinical Data at the 2024 American Academy of Neurology Annual Meeting |
- Analyzing ACADIA Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ACADIA Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining ACADIA Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ACADIA Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ACADIA Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ACADIA Pharmaceuticals' stock. These opinions can provide insight into ACADIA Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.Note that the ACADIA Pharmaceuticals information on this page should be used as a complementary analysis to other ACADIA Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for ACADIA Stock analysis
When running ACADIA Pharmaceuticals' price analysis, check to measure ACADIA Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACADIA Pharmaceuticals is operating at the current time. Most of ACADIA Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ACADIA Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ACADIA Pharmaceuticals' price. Additionally, you may evaluate how the addition of ACADIA Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is ACADIA Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Revenue Per Share 4.434 | Quarterly Revenue Growth 0.693 | Return On Assets (0.07) | Return On Equity (0.15) |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.